Navigation Links
Dr. Arun Sreekumar lectures on new candidate biomarker at Annual EAU Congress
Date:3/10/2009

Arnhem, 10 March 2009 -- The standard Prostate Specific Antigen (PSA) test for prostate cancer cannot tell the difference between aggressive and slow-growing forms. At the Annual EAU Congress, which will be held from 17 to 21 March 2009 in Stockholm (SE), Dr. Arun Sreekumar - University of Michigan (US) - will report about a possible breakthrough biomarker that can supposedly discriminate between aggressive and non-aggressive prostate cancers: sarcosine.

"The PSA test," explained Dr. Sreekumar to US media, "is the clinical standard test, but it has a very high false positive rate." Sreekumar underlined that there is a danger to overtreat some patients or not to treat others. Quite often men have PSA scores that fall into a grey area. Then an invasive biopsy is needed to clarify a diagnosis. But even when a biopsy reveals cancer, it sometimes remains unclear whether the cancer is aggressive or indolent. Thus a biopsy does not always reveal who needs aggressive treatment.

Dr. Arun Sreekumar and his team of the University of Michigan measured the levels of chemical by-products, metabolites, of the reaction inside the human cells. Ten metabolites were found at much higher levels in prostate cancer than in normal samples and one of these metabolites stood out: sarcosine. Sarcosine can be identified in urine, which makes a possible test less invasive than PSA test, which requires a blood analysis.

The findings suggest that not only is sarcosine a marker of cancer aggressiveness, it also has a role in endowing a cancer with malignant properties. Sarcosine may distinguish slow-growing prostate cancers from those likely to spread and become lethal. On the other hand benign prostate cells take on cancerous characteristics in lab dishes when exposed to sarcosine.

"Metabolic profiles delineate potential role for sarcosine in prostate cancer progression" is the title of Sreekumar's scientific article published in Nature recently (Nature, 457, 12 February 2009: 910-914). The research of Sreekumar and his team looked at more than 1,000 metabolites, or small molecules, in tissues associated with prostate cancer.

Dr. Arun Sreekumar, 37-year old lead author of the publication, recently started his new assistant professorship at the Medical College of Georgia Cancer Research Center. His work has been aiming at finding non-invasive ways to identify prostate cancer and predict its aggressiveness.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
0031-263-890-680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Ramsey, N.J. Therapists Lectures to International Medical Professionals & Provides Treatment to Professional Athletes at Home and Abroad
2. Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health
3. Plenary lectures announced for worlds largest osteoporosis congress
4. FDA Clears Cellectars IND Application for Lead Drug Candidate
5. Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
6. Pharmacy Technician Certification Board (PTCB) Unveils New Testing Features for 2009: PTCB Exam to be Offered Daily; Test Results Given to Candidates Immediately in 2009
7. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
8. New Criteria Could Expand Number of Liver Transplant Candidates
9. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
10. Employers “Vote” on Presidential Candidates' Health Care Platforms: Prefer Middle Ground Between the Two Approaches
11. In Final 72-Hour Push, SEIU Members Get Out The Vote for Barack Obama and Other Working Family Candidates Across the Country
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: